
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is poised for significant growth due to its robust pipeline, particularly the promising therapies BDTX-4933 and BDTX-1535 targeting oncogenic mutations. The company's recent findings, including a 60% clinical overall response rate (cORR) for silevertinib and the potential to capture a lucrative first-line non-small cell lung cancer (NSCLC) market exceeding $1 billion, further substantiate a positive outlook on its stock. Additionally, anticipated value inflection points from upcoming trials could enhance investor confidence, driving substantial upside in the company’s valuations.
Bears say
The financial outlook for Black Diamond Therapeutics Inc. is compromised by reduced confidence in the replicability of reported outcomes related to its drug silevertinib, particularly at lower dosing levels. Additionally, the overall efficacy metrics are underwhelming, with the company's clinical results falling short in comparison to competing drugs, such as firmo's cORR in phase 3 trials. The current market capitalization of approximately $230 million reflects a bearish sentiment towards the company's prospects, driven by concerns over its competitive positioning and potential enrollment discrepancies in its clinical trials.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares